Opinion Polls: Delphi's Polling Place

Hosted by Showtalk

Opinion polls on all subjects. Opinions? Heck yes, we have opinions - but we're *always* nice about it, even when ours are diametrically opposed to yours. Register your vote today!

  • 4343
    MEMBERS
  • 87821
    MESSAGES
  • 69
    POSTS TODAY

Discussions

FDA advisors to vote on boosters. What?   The Healthy You: Health and Fitness Polls

Started Sep-17 by Showtalk; 237 views.
Showtalk

Poll Question From Showtalk

Sep-17

FDS panel vote on boosters - what is wrong with this picture?
  • They should follow the science, not vote on opinions0  votes
    0%
  • They should be alarmed by 2 officials who quit and postpone a decision0  votes
    0%
  • Medicine by vote is bad medicine1  vote
    6%
  • This all seems very political2  votes
    13%
  • All of the above10  votes
    66%
  • I trust the FDA to make the right decision2  votes
    13%
  • Other0  votes
    0%
They should follow the science, not vote on opinions 
They should be alarmed by 2 officials who quit and postpone a decision 
Medicine by vote is bad medicine 
This all seems very political 
All of the above 
I trust the FDA to make the right decision 
Other 
In reply toRe: msg 1
Showtalk
Host

From: Showtalk 

Sep-17

FDA advisers to vote on Pfizer's COVID-19 booster shots

Their vote isn't binding, but it's a key step toward allowing a third dose of Pfizer's vaccine in the U.S.

In reply toRe: msg 2
Showtalk
Host

From: Showtalk 

Sep-17

That should say FDA.

In reply toRe: msg 3
Showtalk
Host

From: Showtalk 

Sep-17

That was a short-lived worry but the poll is still valid.  
 

WASHINGTON (AP) — An influential federal advisory panel has soundly rejected a plan to offer Pfizer booster shots against COVID-19 to most Americans.

The vote Friday, 16-3, was a blow to the Biden administration’s effort to shore up people’s protection against the virus amid the highly contagious delta variant.

Over several hours of discussion, members of the Food and Drug Administration panel of outside experts voiced frustration that Pfizer had provided little data on safety of extra doses.

And they complained that data provided by Israeli researchers about their booster campaign might not be suitable for predicting the U.S. experience.

TOP